JP2022541435A5 - - Google Patents
Info
- Publication number
- JP2022541435A5 JP2022541435A5 JP2022502205A JP2022502205A JP2022541435A5 JP 2022541435 A5 JP2022541435 A5 JP 2022541435A5 JP 2022502205 A JP2022502205 A JP 2022502205A JP 2022502205 A JP2022502205 A JP 2022502205A JP 2022541435 A5 JP2022541435 A5 JP 2022541435A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr1
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193280A JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875416P | 2019-07-17 | 2019-07-17 | |
| US62/875,416 | 2019-07-17 | ||
| PCT/US2020/042573 WO2021011885A1 (en) | 2019-07-17 | 2020-07-17 | Claudin18 antibodies and methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193280A Division JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541435A JP2022541435A (ja) | 2022-09-26 |
| JP2022541435A5 true JP2022541435A5 (enExample) | 2023-07-26 |
Family
ID=74211179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502205A Pending JP2022541435A (ja) | 2019-07-17 | 2020-07-17 | クローディン１８抗体及びがんを処置する方法 |
| JP2024193280A Pending JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193280A Pending JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12345709B2 (enExample) |
| EP (1) | EP3999548A4 (enExample) |
| JP (2) | JP2022541435A (enExample) |
| KR (2) | KR20250044762A (enExample) |
| CN (1) | CN114364701A (enExample) |
| AU (2) | AU2020313978B2 (enExample) |
| BR (1) | BR112022000371A2 (enExample) |
| CA (1) | CA3146665A1 (enExample) |
| IL (2) | IL313807A (enExample) |
| MX (1) | MX2022000652A (enExample) |
| WO (1) | WO2021011885A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン１８抗体及びそれらの使用の方法 |
| CN114364701A (zh) | 2019-07-17 | 2022-04-15 | 加利福尼亚大学董事会 | 密封蛋白18抗体和治疗癌症的方法 |
| AU2021354827A1 (en) * | 2020-09-30 | 2023-06-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| EP4335873A4 (en) * | 2021-05-08 | 2025-03-19 | RemeGen Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF |
| JP7901102B2 (ja) * | 2021-06-15 | 2026-08-05 | ゼンコア インコーポレイテッド | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
| WO2022268200A1 (zh) * | 2021-06-25 | 2022-12-29 | 信达生物制药(苏州)有限公司 | 针对密蛋白18.2的抗体及其用途 |
| KR20240044467A (ko) * | 2021-08-09 | 2024-04-04 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도 |
| WO2023078386A1 (zh) * | 2021-11-05 | 2023-05-11 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| WO2023196742A1 (en) * | 2022-04-08 | 2023-10-12 | Fred Hutchinson Cancer Center | Anti-cd90 antibodies, binding fragments, and uses thereof |
| KR20250069817A (ko) * | 2022-06-03 | 2025-05-20 | 라노바 메디신즈 리미티드 | Pd-1 또는 pd-l1 억제제 및 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트를 사용한 암 치료 |
| IL321037A (en) * | 2022-11-30 | 2025-07-01 | Shanghai Chia Tai Tianqing Pharmaceutical Tech Development Co Ltd | Anti-cldn18.2 antibody-drug conjugate, and pharmaceutical composition thereof and use thereof |
| JP2026501506A (ja) * | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025206223A1 (ja) * | 2024-03-28 | 2025-10-02 | 早智子 月田 | 抗ヒトクローディン１８．２抗体及びその使用 |
| KR20250154059A (ko) | 2024-04-19 | 2025-10-28 | 강원대학교산학협력단 | Cldn18 단백질 또는 이를 코딩하는 유전자, 또는 프로모터 부위가 메틸화된 cldn18을 유효성분으로 포함하는 폐포 내 미세먼지 노출 진단용 바이오마커 조성물 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药（上海）有限公司 | 抗密蛋白18a2的抗体及其应用 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| MX2020009326A (es) * | 2018-03-08 | 2020-10-08 | Phanes Therapeutics Inc | Anticuerpos anti-claudina 18.2 y usos de los mismos. |
| BR112021002032A2 (pt) * | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN114364701A (zh) | 2019-07-17 | 2022-04-15 | 加利福尼亚大学董事会 | 密封蛋白18抗体和治疗癌症的方法 |
-
2020
- 2020-07-17 CN CN202080062500.1A patent/CN114364701A/zh active Pending
- 2020-07-17 BR BR112022000371A patent/BR112022000371A2/pt unknown
- 2020-07-17 CA CA3146665A patent/CA3146665A1/en active Pending
- 2020-07-17 WO PCT/US2020/042573 patent/WO2021011885A1/en not_active Ceased
- 2020-07-17 JP JP2022502205A patent/JP2022541435A/ja active Pending
- 2020-07-17 KR KR1020257007047A patent/KR20250044762A/ko active Pending
- 2020-07-17 IL IL313807A patent/IL313807A/en unknown
- 2020-07-17 EP EP20839947.7A patent/EP3999548A4/en active Pending
- 2020-07-17 KR KR1020227004165A patent/KR102777693B1/ko active Active
- 2020-07-17 MX MX2022000652A patent/MX2022000652A/es unknown
- 2020-07-17 AU AU2020313978A patent/AU2020313978B2/en active Active
- 2020-07-17 US US17/627,540 patent/US12345709B2/en active Active
- 2020-07-17 IL IL289663A patent/IL289663B2/en unknown
-
2022
- 2022-10-03 US US17/959,104 patent/US11834499B1/en active Active
-
2024
- 2024-11-01 JP JP2024193280A patent/JP2025032078A/ja active Pending
-
2025
- 2025-05-27 US US19/219,107 patent/US20260104418A1/en active Pending
- 2025-08-04 AU AU2025210899A patent/AU2025210899A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7844420B2 (ja) | 新規二重特異性ポリペプチド複合体 | |
| Strohl | Current progress in innovative engineered antibodies | |
| US9988450B2 (en) | Anti-PD1 antibodies and their use as therapeutics and diagnostics | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP6708635B2 (ja) | ＣＤ３εおよびＲＯＲ１に対する二特異性抗体 | |
| KR102826081B1 (ko) | Lag-3-결합 분자 및 그 사용 방법 | |
| US20230391882A1 (en) | Combination treatment | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JP7611931B2 (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2022525478A5 (enExample) | ||
| JP7565117B2 (ja) | 抗ｔｉｇｉｔ抗体およびその使用 | |
| RS67220B1 (sr) | Humanizovana ili himerna cd3 antitela | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| KR20240055080A (ko) | Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도 | |
| CA3228641A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2025508317A5 (enExample) | ||
| JP2024541476A5 (enExample) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| AU2021224787A1 (en) | CD137 binding molecules and uses thereof | |
| JP7812988B2 (ja) | Ｌｅｗｉｓ Ｙに対するヒト化抗体 | |
| TW202241967A (zh) | 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物 | |
| US20240010701A1 (en) | Combination therapies for treating urothelial carcinoma | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen |